Sponsored By

The Minneapolis, MN-based company would use GE Healthcare's ultrasound imaging platform to power visualization features of its sonic beam therapy.

MDDI Staff

May 23, 2022

2 Min Read
IMG_2022-5-23-103935.jpg
Image courtesy of filmfoto / Alamy Stock Photo

HistoSonics and GE Healthcare have entered into an agreement that could have major implications for liver treatment. Under the agreement, HistoSonics would use GE Healthcare's LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of its sonic beam therapy.  

The Minneapolis, MN-based company said as part of the agreement and upon market authorization, it would distribute the LOGIQ E10 Series on a one-to-one basis with its breakthrough liver therapy system.

HistoSonics said its non-invasive platform combines advanced imaging and proprietary software to deliver patient specific treatments using histotripsy to mechanically destroy and liquify targeted tissues at a sub-cellular level.  The company said it believes the technology's mechanism of action could offer significant advantages to patients, including precise and predictable treatment zones with equivalent treatment effect throughout the entire treated volume.

Early clinical and pre-clinical results also suggest that histotripsy largely preserves critical structures such as the liver capsule, and larger vessels and bile ducts within or adjacent to the treated volume of tissue. Additionally, histotripsy enables the treating physicians to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today.

The agreement between GE Healthcare and HistoSonics comes as HistoSonics continues enrollment in their U.S. and European #HOPE4LIVER Trials, evaluating the safety and efficacy of histotripsy for the destruction of targeted primary or metastatic liver tumors.  The company announced it won breakthrough device designation for the device in October of 2021.

"We are very excited to formalize our imaging partnership with GE Healthcare, which is a key part of bringing our transformative therapy platform, and an entirely new treatment option, to the clinic and to patients," said Josh Stopek, HistoSonics Vice President of R&D.  "We've developed a very collaborative relationship with GE Healthcare and look forward to expanding our efforts to realize the full potential of histotripsy across clinical applications, specialties, and care settings."

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like